About US
Contact us
-
Merck’s Keytruda gets FDA approval to treat kidney cancerMerck has received US Food and Drug Administration (FDA) approval for its anti-PD-1 therapy Keytruda to treat advanced renal cell carcinoma (RCC) patients. The approval allows the drug to be used in2019/4/24
-
Federal judge scolds Purdue, Endo and Mallinckrodt for stall tactics in opioids caseU.S. District Judge Dan Polster has had enough of opioids makers Purdue Pharma, Endo and Mallinckrodt asking for extensions in the multistate lawsuit against them. And he said as much Thursday in the2019/4/23
-
Bausch Health is far from the LeBron James in eye care, so don't compare it to Alcon: analystAfter Novartis eye care spinoff Alcon made a successful debut on the Swiss Exchange earlier this month, some analysts used it as an argument to make a bullish case for Bausch Health. But one analyst2019/4/23
-
Gorsky says military service had 'profound effect' on his reign as J&J chiefWhat does it take to steer one of pharma’s biggest whales? As Johnson & Johnson CEO Alex Gorsky told Fortune magazine, six years in the U.S. Army made all the difference. Gorsky, the $20-million-2019/4/22
-
Roche throws in the towel on Tecentriq bladder, myeloma trialsRoche’s Tecentriq has scored some important victories lately, including a pair of first-in-class approvals. But in other types of cancer, the Swiss drugmaker has decided to pull the plug. In a Wednes2019/4/22
-
Lonza plagued by supply problems after China plant explosionAn explosion at a chemical plant in China that killed 62 people not only exposed weaknesses in China’s safety oversight but it also exposed weaknesses in the global ingredient supply chain. Thedisrup2019/4/19
-
United Therapeutics teamed with pumpmaker to block Remodulin generics, Sandoz suit saysIt took Novartis' Sandoz years to reach the market with a generic to United Therapeutics’ pulmonary arterial hypertension drug Remodulin, but last month, the company managed to do just that. Now, t2019/4/19
-
Teva CEO Kåre Schultz nabs whopping $33M in first full year at the helmIf you thought Teva had gone big-time with its 2017 pay package for CEO Kåre Schultz, check out what it paid him in 2018. The Israeli drugmakerforked over(PDF) a whopping $32.5 million to its chief e2019/4/18
-
Feds oppose white-coat kickbacks suit out of 'animus' against whistleblowers: judgeA group of whistleblowers made waves in pharma by suing numerous drugmakers, claiming the companiesused nurse educators and other services as kickbacks to boost prescriptions. But insteadof jumping2019/4/18
-
Struggling Insys swaps CEOs as Subsys marketing crackdown continuesInsys has weathered years of litigation, investigations and allegations of illegal sales practices to pump up powerful painkiller Subsys. Now, hoping to revamp its business and its rep, the company2019/4/17